Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association …
…, DE Casey Jr, TJ Gardner, PB Lockhart, DJ Moliterno… - Circulation, 2007 - Am Heart Assoc
Dual antiplatelet therapy with aspirin and a thienopyridine has been shown to reduce
cardiac events after coronary stenting. However, many patients and healthcare providers …
cardiac events after coronary stenting. However, many patients and healthcare providers …
Stent thrombosis
…, SG Ellis, DO Williams, T Kimura, DJ Moliterno - Journal of the American …, 2010 - jacc.org
Intense investigation continues on the pathobiology of stent thrombosis (ST) because of its
morbidity and mortality. Because little advance has been made in outcomes following ST, …
morbidity and mortality. Because little advance has been made in outcomes following ST, …
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary …
Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y 12 receptor inhibitor is the standard
treatment for patients undergoing percutaneous coronary intervention. The availability of …
treatment for patients undergoing percutaneous coronary intervention. The availability of …
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials
E Boersma, RA Harrington, DJ Moliterno, H White… - The Lancet, 2002 - thelancet.com
Background Platelet glycoprotein IIb/IIIa inhibitors have been shown to reduce cardiac
complications in patients undergoing percutaneous coronary intervention. The clinical efficacy of …
complications in patients undergoing percutaneous coronary intervention. The clinical efficacy of …
[HTML][HTML] Thrombin-receptor antagonist vorapaxar in acute coronary syndromes
P Tricoci, Z Huang, C Held, DJ Moliterno… - … England Journal of …, 2012 - Mass Medical Soc
Background Vorapaxar is a new oral protease-activated–receptor 1 (PAR-1) antagonist that
inhibits thrombin-induced platelet activation. Methods In this multinational, double-blind, …
inhibits thrombin-induced platelet activation. Methods In this multinational, double-blind, …
[HTML][HTML] Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary …
EJ Topol, DJ Moliterno, HC Herrmann… - … England Journal of …, 2001 - Mass Medical Soc
Background In the setting of percutaneous coronary revascularization, agents in the class
known as platelet glycoprotein IIb/IIIa inhibitors have significantly reduced the incidence of …
known as platelet glycoprotein IIb/IIIa inhibitors have significantly reduced the incidence of …
Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes
…, CB Granger, LK Newby, PW Armstrong, DJ Moliterno… - Jama, 2004 - jamanetwork.com
ContextIt is unclear if blood transfusion in anemic patients with acute coronary syndromes is
associated with improved survival.ObjectiveTo determine the association between blood …
associated with improved survival.ObjectiveTo determine the association between blood …
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study
Background Dual antiplatelet therapy (DAPT) cessation increases the risk of adverse events
after percutaneous coronary intervention (PCI). Whether risk changes over time, depends …
after percutaneous coronary intervention (PCI). Whether risk changes over time, depends …
Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction
…, HJ White, HB Cheek, JW Moses, DJ Moliterno… - Circulation, 1998 - Am Heart Assoc
Background—The benefit of catheter-based reperfusion for acute myocardial infarction (MI)
is limited by a 5% to 15% incidence of in-hospital major ischemic events, usually caused by …
is limited by a 5% to 15% incidence of in-hospital major ischemic events, usually caused by …
ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology …
…, S Kaul, JA Linderbaum, DJ Moliterno… - Journal of the American …, 2012 - jacc.org
This document was approved by the American College of Cardiology Foundation (ACCF)
Board of Trustees in August 2012 and by the following societies in August 2012: American …
Board of Trustees in August 2012 and by the following societies in August 2012: American …